Jeffrey Bartlett, Ph.D., serves as Rampart’s chief innovation and technical officer, leading scientific discovery and biotherapeutic development. For three decades, Dr. Bartlett has dedicated his career to helping bring novel treatments to children with rare diseases, with a focus on advancing gene and cell-based therapies. Most recently, he served as senior director of gene therapy strategic development at CSL Behring, a global rare disease biotech company. Previously, he was chief scientific officer and senior vice president of research and development for Calimmune, a biotechnology company developing gene-modified stem cell and T cell therapies for HIV. (Calimmune was acquired by CSL Behring in 2017.) Earlier, Dr. Bartlett served for more than a decade at The Ohio State University in dual roles as associate professor of pediatrics and associate professor of molecular virology, immunology and medical genetics. During that time, he was also an investigator for the Center for Gene Therapy and Center for Childhood Cancer at Nationwide Children’s Hospital in Columbus, Ohio. Dr. Bartlett also was previously research assistant professor in the Pulmonary and Cystic Fibrosis Research Center at University of North Carolina’s Department of Medicine. He earned a Ph.D. from the University of Pittsburgh School of Medicine and a bachelor’s degree in Biology and Art from Middlebury College.